Connection

Taishi Yonezawa to Humans

This is a "connection" page, showing publications Taishi Yonezawa has written about Humans.
Connection Strength

0.088
  1. The E3 ligase DTX2 inhibits RUNX1 function by binding its C terminus and prevents the growth of RUNX1-dependent leukemia cells. FEBS J. 2023 11; 290(21):5141-5157.
    View in: PubMed
    Score: 0.024
  2. The ubiquitin ligase RNF38 promotes RUNX1 ubiquitination and enhances RUNX1-mediated suppression of erythroid transcription program. Biochem Biophys Res Commun. 2018 11 02; 505(3):905-909.
    View in: PubMed
    Score: 0.017
  3. The ubiquitin ligase STUB1 regulates stability and activity of RUNX1 and RUNX1-RUNX1T1. J Biol Chem. 2017 07 28; 292(30):12528-12541.
    View in: PubMed
    Score: 0.016
  4. Clonal hematopoiesis-related mutant ASXL1 promotes atherosclerosis in mice via dysregulated innate immunity. Nat Cardiovasc Res. 2024 Dec; 3(12):1568-1583.
    View in: PubMed
    Score: 0.007
  5. IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia. EMBO Mol Med. 2023 01 11; 15(1):e15631.
    View in: PubMed
    Score: 0.006
  6. A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells. Cell Rep. 2021 08 24; 36(8):109576.
    View in: PubMed
    Score: 0.005
  7. HHEX promotes myeloid transformation in cooperation with mutant ASXL1. Blood. 2020 10 01; 136(14):1670-1684.
    View in: PubMed
    Score: 0.005
  8. Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms. Sci Rep. 2019 06 03; 9(1):8171.
    View in: PubMed
    Score: 0.004
  9. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nat Commun. 2018 07 16; 9(1):2733.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.